Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
IDXX Stock Forecast 2026-2027
$540.68
Current Price
$42.65B
Market Cap
Buy 9
Hold 5
Sell 1
Wall St Analyst Ratings
Distance to IDXX Price Targets
+48.9%
To High Target of $805.00
+31.8%
To Median Target of $712.50
-13.1%
To Low Target of $470.00
IDXX Price Momentum
-3.2%
1 Week Change
-5.6%
1 Month Change
+3.9%
1 Year Change
-20.1%
Year-to-Date Change
-29.8%
From 52W High of $769.98
+6.7%
From 52W Low of $506.91
📊 TOP ANALYST CALLS
Did IDXX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if IDEXX is one of their latest high-conviction picks.
Latest IDXX Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, IDXX has a bullish consensus with a median price target of $712.50 (ranging from $470.00 to $805.00). The overall analyst rating is Buy (7.7/10). Currently trading at $540.68, the median forecast implies a 31.8% upside. This outlook is supported by 9 Buy, 5 Hold, and 1 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
IDXX Analyst Ratings
9
Buy
5
Hold
1
Sell
IDXX Price Target Range
Low
$470.00
Average
$712.50
High
$805.00
Current: $540.68
Latest IDXX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for IDXX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 28, 2026 | UBS | Andrea Alfonso | Neutral | Maintains | $640.00 |
| Apr 15, 2026 | Citigroup | Neutral | Initiates | $N/A | |
| Mar 31, 2026 | Stifel | Buy | Maintains | $N/A | |
| Feb 9, 2026 | Piper Sandler | Neutral | Maintains | $N/A | |
| Feb 5, 2026 | Barclays | Overweight | Maintains | $N/A | |
| Feb 3, 2026 | UBS | Neutral | Maintains | $N/A | |
| Feb 3, 2026 | BTIG | Buy | Maintains | $N/A | |
| Dec 9, 2025 | Barclays | Overweight | Initiates | $N/A | |
| Nov 4, 2025 | Morgan Stanley | Overweight | Maintains | $N/A | |
| Nov 4, 2025 | UBS | Neutral | Maintains | $N/A | |
| Nov 4, 2025 | JP Morgan | Overweight | Maintains | $N/A | |
| Nov 4, 2025 | BTIG | Buy | Maintains | $N/A | |
| Oct 31, 2025 | Stifel | Buy | Upgrade | $N/A | |
| Oct 1, 2025 | UBS | Neutral | Initiates | $N/A | |
| Aug 15, 2025 | Morgan Stanley | Overweight | Maintains | $N/A | |
| Aug 11, 2025 | Piper Sandler | Neutral | Maintains | $N/A | |
| Aug 4, 2025 | JP Morgan | Overweight | Maintains | $N/A | |
| Aug 4, 2025 | Morgan Stanley | Overweight | Maintains | $N/A | |
| Jul 29, 2025 | Morgan Stanley | Overweight | Maintains | $N/A | |
| Jul 17, 2025 | Leerink Partners | Outperform | Maintains | $N/A |
IDEXX Laboratories, Inc. (IDXX) Competitors
The following stocks are similar to IDEXX based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
IDEXX Laboratories, Inc. (IDXX) Financial Data
IDEXX Laboratories, Inc. has a market capitalization of $42.65B with a P/E ratio of 41.5x. The company generates $4.45B in trailing twelve-month revenue with a 24.6% profit margin.
Revenue growth is +14.3% quarter-over-quarter, while maintaining an operating margin of +31.8% and return on equity of +72.9%.
Valuation Metrics
Market Cap
$42.65B
Enterprise Value
$45.41B
P/E Ratio
41.5x
PEG Ratio
2.4x
Price/Sales
10.0x
Growth & Margins
Revenue Growth (YoY)
+14.3%
Gross Margin
+63.4%
Operating Margin
+31.8%
Net Margin
+24.6%
EPS Growth
+14.7%
Financial Health
Cash/Price Ratio
+0.5%
Current Ratio
1.1x
Debt/Equity
71.0x
ROE
+72.9%
ROA
+26.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
IDEXX Laboratories, Inc. (IDXX) Business Model
About IDEXX Laboratories, Inc.
What They Do
Provides healthcare diagnostics for animals and water.
Business Model
IDEXX Laboratories, Inc. generates revenue by developing and selling diagnostic test kits, in-clinic analyzers, and reference laboratory services primarily for veterinary practices. Additionally, the company offers management software and data analytics tools that enhance clinical decision-making and streamline workflows in veterinary care. Their diverse product offerings also cater to the livestock, poultry, dairy, and water testing markets, ensuring a steady income from multiple sectors.
Additional Information
Founded in 1983 and headquartered in Westbrook, Maine, IDEXX is a key player in animal health diagnostics and environmental testing, with operations segmented into Companion Animal, Water, Livestock, Poultry, and Dairy services. The company's focus on innovation and comprehensive solutions supports food safety and public health monitoring globally.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
11,000
CEO
Mr. Michael G. Erickson Ph.D.
Country
United States
IPO Year
1991
Website
www.idexx.comIDEXX Laboratories, Inc. (IDXX) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Does NVST Stock Still Deserve a Place in Your Portfolio?
Envista executes on growth priorities with new products, acquisitions and global expansion, but macro, tariff and currency headwinds remain in focus.
Jul 09, 2026
By Zacks Equity Research
Analyst Blog
Illumina Stock Gains 43.7% in 2026: What's Powering the Rally?
ILMN stock's 43.7% 2026 rally is fueled by strong sequencing demand, NovaSeq X momentum and progress toward higher growth and profitability.
Jul 09, 2026
By Zacks Equity Research
Analyst Blog
ALC vs. IDXX: Which Stock Is the Better Value Option?
ALC vs. IDXX: Which Stock Is the Better Value Option?
Jul 07, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Investors in the Medical - Instruments sector may consider Alcon (ALC) and Idexx Laboratories (IDXX) as potential undervalued stock options.
Why It Matters
The comparison of Alcon and Idexx Laboratories highlights potential investment opportunities in the Medical - Instruments sector, signaling possible undervaluation and growth prospects.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
IDEXX Laboratories (NASDAQ: IDXX) will release Q2 2026 financial results on August 4, 2026, before market open, followed by an analyst conference call at 8:30 a.m. ET.
Why It Matters
The scheduled earnings release and analyst call for IDEXX Laboratories indicate upcoming insights into financial performance, impacting stock valuation and investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Zacks Style Scores help investors identify top-rated stocks tailored to their investing style, providing a useful tool for stock selection.
Why It Matters
The Zacks Style Scores can help investors identify high-potential stocks tailored to their specific strategies, enhancing portfolio performance and decision-making.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
IDXX stock is experiencing notable activity in the options market, indicating potential investor interest and volatility.
Why It Matters
Increased activity in the options market for IDXX stock may signal changing investor sentiment or expectations about future volatility, influencing stock price movements.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
Zacks Premium offers Style Scores, aiding value, growth, and momentum investors in identifying strong stocks more easily.
Why It Matters
The Zacks Style Scores can enhance stock selection across investment strategies, potentially leading to better returns, making it a valuable tool for informed investment decisions.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Zacks Premium offers Style Scores to help value, growth, and momentum investors identify strong stocks more effectively.
Why It Matters
The Zacks Style Scores enhance stock selection for various investment strategies, potentially leading to better returns and improved portfolio performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About IDXX Stock
What is IDEXX Laboratories, Inc.'s (IDXX) stock forecast for 2027?
Based on our analysis of 2 Wall Street analysts, IDEXX Laboratories, Inc. (IDXX) has a median price target of $712.50. The highest price target is $805.00 and the lowest is $470.00.
Is IDXX stock a good investment in 2027?
According to current analyst ratings, IDXX has 9 Buy ratings, 5 Hold ratings, and 1 Sell ratings. The stock is currently trading at $540.68. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for IDXX stock?
Wall Street analysts predict IDXX stock could reach $712.50 in the next 12 months. This represents a 31.8% increase from the current price of $540.68. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is IDEXX Laboratories, Inc.'s business model?
IDEXX Laboratories, Inc. generates revenue by developing and selling diagnostic test kits, in-clinic analyzers, and reference laboratory services primarily for veterinary practices. Additionally, the company offers management software and data analytics tools that enhance clinical decision-making and streamline workflows in veterinary care. Their diverse product offerings also cater to the livestock, poultry, dairy, and water testing markets, ensuring a steady income from multiple sectors.
What is the highest forecasted price for IDXX IDEXX Laboratories, Inc.?
The highest price target for IDXX is $805.00 from at , which represents a 48.9% increase from the current price of $540.68.
What is the lowest forecasted price for IDXX IDEXX Laboratories, Inc.?
The lowest price target for IDXX is $470.00 from at , which represents a -13.1% decrease from the current price of $540.68.
What is the overall IDXX consensus from analysts for IDEXX Laboratories, Inc.?
The overall analyst consensus for IDXX is bullish. Out of 2 Wall Street analysts, 9 rate it as Buy, 5 as Hold, and 1 as Sell, with a median price target of $712.50.
How accurate are IDXX stock price projections?
Stock price projections, including those for IDEXX Laboratories, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 15, 2026 3:21 AM UTC